Randomized Clinical Trials (France)

RCTs (Randomized Clinical Trials) is a French contract research organization (CRO) headquartered in Lyon. According to its official website, it is an international full-service CRO that has supported pharmaceutical companies, medical device manufacturers, biotech and medtech firms, and academic sponsors in their research projects for more than 35 years. The company positions itself as a partner capable of taking sponsor projects from A to Z, from conception through execution. RCTs organizes its expertise around several clinical research domains: pre-authorization studies, post-authorization studies based on primary data, studies based on secondary data (RNIPH), early access and compassionate use programs, clinical evaluation of medical devices and regulatory consulting, and dedicated support for biotech and medtech companies. It also offers training and digital solutions, and supports international studies. Its teams state that their expertise covers all health products and all therapeutic areas, as well as all types of studies. The company publishes success stories illustrating its work. These include ESCAPADE, a study requested by the authorities; an evaluation of the impact of the delisting (déremboursement) of a therapeutic class by the French national health insurance, using the case of AASAL; a cost-benefit analysis of early versus late knee prosthesis in French patients with gonarthrosis; early access and real-world data work on the cohort ATU for DARATUMUMAB; and CE marking of DBLG1, an innovative technology solution incorporating artificial intelligence. RCTs also reports having contributed to the acoziborole program for human African trypanosomiasis (sleeping sickness), developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, by performing data management and statistical analyses on fexinidazole. RCTs presents itself as an active employer, with a recruitment page on its website, and maintains a presence on LinkedIn and Twitter. Its client base spans the pharmaceutical and medical device industries, emerging biotech and medtech companies, and academic research sponsors. The company's stated mission is to support projects that transform patient care and save lives.

RCTs (Randomized Clinical Trials) is a contract research organization based in Lyon, France. Its official website states that it has supported pharmaceutical companies, medical device manufacturers, biotech and medtech firms, and academic sponsors in their research projects for more than 35 years. This places the company's origins in the late 1980s or early 1990s, although the exact founding year is not specified in the available evidence. Over time, RCTs has developed a full-service CRO model covering the entire clinical research lifecycle. Its service portfolio includes pre-authorization studies, post-authorization studies based on primary data, studies based on secondary data (RNIPH), early access and compassionate use programs, clinical evaluation of medical devices and regulatory consulting, and dedicated support for biotech and medtech companies. The company also offers training and digital solutions, and manages international studies. The company has accumulated experience across all health products and therapeutic areas, and across all types of studies. Its published success stories illustrate the breadth of its work. These include ESCAPADE, a study requested by the authorities; an evaluation of the impact of the delisting of a therapeutic class by the French national health insurance, using the case of AASAL; a cost-benefit analysis of early versus late knee prosthesis in French patients with gonarthrosis; early access and real-world data work on the cohort ATU for DARATUMUMAB; and CE marking of DBLG1, an innovative technology solution incorporating artificial intelligence. In the field of neglected diseases, RCTs reports having contributed to the acoziborole program for human African trypanosomiasis (sleeping sickness), developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi. Specifically, RCTs performed data management and statistical analyses on fexinidazole. The acoziborole program received a positive opinion from the European Medicines Agency's CHMP, based on a Phase II/III study showing up to 96% success at 18 months across all stages of the disease. RCTs maintains a public presence through its website, LinkedIn and Twitter, and actively recruits staff. Its headquarters is in Lyon, France, and it positions itself as an international CRO supporting sponsors in France and abroad.

• RCTs states it has supported pharmaceutical, medical device, biotech, medtech and academic sponsors for more than 35 years.

• Publication of success story on acoziborole for sleeping sickness, noting RCTs' data management and statistical analysis work on fexinidazole.

International full-service CRO based in Lyon, France, serving pharmaceutical, medical device, biotech, medtech and academic sponsors across all therapeutic areas and study types.

• Pre-authorization studies

  Clinical studies conducted before marketing authorization.

• Post-authorization studies on primary data

  Post-authorization research collecting primary data.

• Studies on secondary data (RNIPH)

  Research using secondary data, including RNIPH.

• Early access / compassionate use

  Programs for early access to treatments and compassionate use.

• Clinical evaluation of medical devices / regulatory consulting

  Clinical evaluation and regulatory advice for medical devices.

• Biotech / Medtech support

  Dedicated services for biotech and medtech companies.

• Training

  Training programs offered by RCTs.

• Digital solutions

  Digital solutions for clinical research.

• International studies

  Management of international clinical studies.

1. 1RCTs : CRO full-service en recherche cliniquercts.fr
2. 2Maladie du sommeil/Acoziborole : Success Story RCTsrcts.fr
3. 3Randomized Clinical Trials (France) - Wikidatawikidata.org